Short answer: tirzepatide is the drug; Zepbound® is one FDA-approved brand of it. So when someone asks "is tirzepatide the same as Zepbound?", the honest answer is it depends on which tirzepatide you mean — because the word is used two different ways. This is one of the most common points of confusion in GLP-1 weight care, and the distinction genuinely matters for what you're getting.
Tirzepatide is the active ingredient
Tirzepatide is the name of the medication itself — a dual GLP-1 and GIP receptor agonist that reduces appetite and slows digestion. Eli Lilly developed it and sells it under two FDA-approved brand names, each with a different approved use:
- Zepbound® — FDA-approved tirzepatide for chronic weight management
- Mounjaro® — FDA-approved tirzepatide for type 2 diabetes
So Zepbound® and Mounjaro® both contain tirzepatide. In that sense, yes — Zepbound is tirzepatide. It's the same relationship as "ibuprofen" and "Advil®": one is the drug, the other is a brand of it.
So where does the confusion come from?
Because "tirzepatide" also shows up in another context: compounded tirzepatide, prepared by US-licensed compounding pharmacies. This is not the same thing as Zepbound®, and that's the part people miss.
Important: compounded tirzepatide is not Zepbound®
Compounded tirzepatide is not FDA-approved, is not a generic version of Zepbound® or Mounjaro®, and has not been evaluated by the FDA for safety, efficacy, or quality. The clinical trial results for Zepbound® (such as the SURMOUNT studies) were conducted on the FDA-approved product and have not been clinically established for compounded preparations. Compounded medications are prepared on a per-patient basis when a licensed clinician documents a specific clinical need.
Zepbound® vs compounded tirzepatide, side by side
| Zepbound® | Compounded tirzepatide | |
|---|---|---|
| What it is | FDA-approved brand product (Eli Lilly) | Prepared per-patient by a US-licensed compounding pharmacy |
| FDA approval | Yes — for chronic weight management | No — not FDA-approved, not a generic |
| Clinical trials | Studied in the SURMOUNT program | Brand trial results do not transfer to compounded preparations |
| Regulatory oversight | FDA (drug approval) | State boards of pharmacy (compounding) |
| Typical format | Prefilled pen / single-dose vials | Vial and syringe |
| Cost without insurance | ~$1,300/mo list price | Lower; varies by pharmacy and program |
Why does any of this matter to me?
Two practical reasons:
-
What you're actually taking. If a provider prescribes Zepbound®, you're getting the FDA-approved product. If they prescribe compounded tirzepatide, you're getting a per-patient preparation that is regulated differently and has a different evidence base — even though the underlying molecule is tirzepatide.
-
Cost and access. Brand-name Zepbound® runs around $1,300/month at list price without insurance. Compounded tirzepatide is generally less expensive, which is why it exists as an option — but price alone is not a sufficient reason to compound under FDA guidance; there has to be a documented patient-specific clinical reason. A licensed clinician decides what's appropriate for you.
At Pallas, compounded tirzepatide injection is $359/mo when a clinician determines it's clinically appropriate, and we also dispense FDA-approved brand-name Zepbound® through US-licensed pharmacies — both cash-pay; insurance is not billed.
Ready to see if you qualify?
A licensed Pallas provider can review your health history and confirm eligibility in under 2 minutes.
Start your intake →Is Mounjaro the same as Zepbound, then?
Almost — both are tirzepatide made by Eli Lilly, so they share the same active ingredient. The difference is the FDA-approved use: Zepbound® is approved for weight management; Mounjaro® is approved for type 2 diabetes. They're priced and covered differently because of those indications.
For a fuller comparison of the molecules and the brands, see our guides on semaglutide vs tirzepatide and Wegovy vs Zepbound.
Frequently asked questions
Tirzepatide is the drug; Zepbound is the FDA-approved brand name for tirzepatide used for weight management. So FDA-approved Zepbound is tirzepatide. However, compounded tirzepatide is not the same as Zepbound — it is not FDA-approved, not a generic, and has not been evaluated by the FDA for safety, efficacy, or quality.
No. Compounded tirzepatide is prepared per-patient by US-licensed compounding pharmacies and is not FDA-approved, is not a generic version of Zepbound, and has not been evaluated by the FDA. Clinical trial results for Zepbound do not apply to compounded preparations.
Both are tirzepatide made by Eli Lilly, so they contain the same active ingredient. They differ in FDA-approved use: Zepbound is approved for chronic weight management, while Mounjaro is approved for type 2 diabetes.
A licensed clinician may consider a compounded preparation when they document a specific clinical reason that an FDA-approved product is not appropriate for a particular patient. Cost or preference alone is not a sufficient basis for compounding under FDA guidance.
Both, when clinically appropriate. Pallas dispenses FDA-approved Zepbound through US-licensed pharmacies, and also offers compounded tirzepatide prepared by US-licensed compounding pharmacies. Both are cash-pay; insurance is not billed. A licensed clinician determines which is appropriate for you.
Bottom line: Tirzepatide is the medication; Zepbound® is the FDA-approved brand of it for weight loss. "Tirzepatide" can also mean a compounded preparation, which is not the same as Zepbound® — not FDA-approved and regulated differently. Knowing which one you're being prescribed tells you exactly what you're getting.
Not sure which option fits you?
A licensed Pallas provider can review your history and explain whether brand-name or compounded is appropriate — usually by message.
Start your intake →